InNexus Biotechnology Develops New EGFR Antibody

InNexus Biotechnology has developed a new antibody product from its DXL platform technology, DXL1218 (EGFR), for the potential treatment of colorectal cancer.
   
“Recent experimental data suggests that DXL1218 (EGFR) is superior to competing commercialized products on the market, such as Erbitux, in terms of potency and efficacy,” said Jeff Morhet, chief executive officer and chairman of InNexus. “I am very excited, as this latest development lends further support to the robustness and predictability of the DXL platform and the superiority of products from the platform over presently commercialized offerings.”
   
Research partner, Pablo Legorreta, chief executive officer of Royalty Pharma, said, “We are quite pleased with the rapid progress of InNexus. Jeff has had a vision for rapid product development based on DXL technology coupled with advanced in vivo studies and a significant regulatory strategy. We look forward to their continued rollout of products and performance.”